Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Ana Zabalza de Torres

Ana Zabalza de Torres

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Ana Zabalza de Torres

Ana Zabalza de Torres

Ana Zabalza de Torres

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...

IP: -
Collaborators: Jordi Rio Izquierdo, Ana Zabalza de Torres, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140360
Reference: PI20/01697
Duration: 01/01/2021 - 30/06/2025

TRAtamiento y recuperación VISual en neuritis óptica - Estudio TRAVIS

IP: Jaume Sastre Garriga
Collaborators: Dulce María Moncho Rodríguez, Sergio Cabello, Cristina Auger Acosta, Alex Rovira Cañellas, Ana Zabalza de Torres, Joaquin Castillo Justribo
Funding agency: Instituto de Salud Carlos III
Funding: 96800
Reference: PI19/00950
Duration: 01/01/2020 - 30/06/2024

Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)

IP: -
Collaborators: Carlos Nos Llopis, Gabriel Ig Camiña Rodríguez, Ana Zabalza de Torres, Luciana Midaglia Fernandez
Funding agency: The Innovative Medicines Initiative
Funding: 552235
Reference: RADAR_X.MONTALBAN_IMI2_2015
Duration: 01/04/2016 - 31/03/2022

Related news

Dr. Xavier Montalban, Dr. Mar Tintoré and Dr. René Carvajal

Age and treatment may predict risk of multiple sclerosis reactivation

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

Laboratori

Viva in Vitro and Vall d’Hebron will study biomarkers in multiple sclerosis

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Dr Mar Tintoré and Dr Álvaro Cobo Calvo

Ovarian reserve does not predict the course of multiple sclerosis

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

See more

Related professionals

Teresa Soriano Sánchez

Teresa Soriano Sánchez

Senior researcher
Cardiovascular Diseases
Read more
Luis Ignacio Soto Bargaria

Luis Ignacio Soto Bargaria

Predoctoral researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more
Judith Sacanell Lacasa

Judith Sacanell Lacasa

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Susana Anfosso Llopis

Susana Anfosso Llopis

Research assistant
Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.